Indication: Relapsed/Refractory Solid Cancers
AN OPEN-LABEL, MULTICENTER, PHASE I STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID CANCERS
Sub-indication: Miscellaneous Malignancies
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: IGM Biosciences
